Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Open in API
Filings indexed 2,379 across all filing types
Latest filing 2025-05-05 Director's Dealing
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-05-05 English
FORM 4
Director's Dealing
2025-05-05 English
FORM 4
Director's Dealing
2025-05-05 English
FORM 4
Director's Dealing
2025-05-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 5, 2025, reporting the issuance of a press release containing consolidated financial results for the quarter ended March 31, 2025. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference, but the document itself does not contain detailed financial statements or substantive financial data. The length is 3576 characters, which is relatively short and consistent with a current report announcing earnings results rather than the earnings release itself. According to the classification rules, such a Form 8-K reporting earnings results is best classified as an Earnings Release (ER) since it announces quarterly financial results. The document is not a full quarterly report (IR), nor is it a regulatory filing without substantive data (RNS). Therefore, the appropriate classification is ER with high confidence.
2025-05-05 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from Vertex Pharmaceuticals to the SEC responding to comments on their previously filed Form 10-K for the fiscal year ended December 31, 2024. It references the 10-K filing and discusses planned future disclosures in response to SEC staff comments. The document is a correspondence letter addressing regulatory comments rather than the 10-K report itself. It is short (2904 characters) and serves as a regulatory response, not a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory correspondence and not the actual annual report or audit report.
2025-05-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.